ASL, DSC, DCE perfusion MRI and 18F-DOPA PET/CT in differentiating glioma recurrence from post-treatment changes.

Autor: Moltoni G; NESMOS, Department of Neuroradiology, S. Andrea Hospital, University Sapienza, Via di Grottarossa 1035/1039, 00189, Rome, Italy. giulia.moltoni@uniroma1.it., Romano A; NESMOS, Department of Neuroradiology, S. Andrea Hospital, University Sapienza, Via di Grottarossa 1035/1039, 00189, Rome, Italy., Capriotti G; Department of Medical-Surgical Sciences and Translational Medicine, University of Rome 'Sapienza', Rome, Italy., Campagna G; Department of Medical-Surgical Sciences and Translational Medicine, University of Rome 'Sapienza', Rome, Italy., Ascolese AM; SMCMT Department, Radiotherapy Oncology, S. Andrea Hospital, University Sapienza, Rome, Italy., Romano A; NESMOS, Department of Neuroradiology, S. Andrea Hospital, University Sapienza, Via di Grottarossa 1035/1039, 00189, Rome, Italy., Dellepiane F; NESMOS, Department of Neuroradiology, S. Andrea Hospital, University Sapienza, Via di Grottarossa 1035/1039, 00189, Rome, Italy., Minniti G; Department of Radiological, Oncological and Pathological Sciences, 'Sapienza' University of Rome, 00138, Rome, Italy.; IRCCS Neuromed, 86077, Pozzilli, Italy., Signore A; Department of Medical-Surgical Sciences and Translational Medicine, University of Rome 'Sapienza', Rome, Italy., Bozzao A; NESMOS, Department of Neuroradiology, S. Andrea Hospital, University Sapienza, Via di Grottarossa 1035/1039, 00189, Rome, Italy.
Jazyk: angličtina
Zdroj: La Radiologia medica [Radiol Med] 2024 Sep; Vol. 129 (9), pp. 1382-1393. Date of Electronic Publication: 2024 Aug 08.
DOI: 10.1007/s11547-024-01862-3
Abstrakt: Objectives: To discriminate between post-treatment changes and tumor recurrence in patients affected by glioma undergoing surgery and chemoradiation with a new enhancing lesion is challenging. We aimed to evaluate the role of ASL, DSC, DCE perfusion MRI, and 18F-DOPA PET/CT in distinguishing tumor recurrence from post-treatment changes in patients with glioma.
Materials and Methods: We prospectively enrolled patients with treated glioma (surgery plus chemoradiation) and a new enhancing lesion doubtful for recurrence or post-treatment changes. Each patient underwent a 1.5T MRI examination, including ASL, DSC, and DCE PWI, and an 18 F-DOPA PET/CT examination. For each lesion, we measured ASL-derived CBF and normalized CBF, DSC-derived rCBV, DCE-derived Ktrans, Vp, Ve, Kep, and PET/CT-derived SUV maximum. Clinical and radiological follow-up determined the diagnosis of tumor recurrence or post-treatment changes.
Results: We evaluated 29 lesions (5 low-grade gliomas and 24 high-grade gliomas); 14 were malignancies, and 15 were post-treatment changes. CBF ASL, nCBF ASL, rCBV DSC, and PET SUVmax were associated with tumor recurrence from post-treatment changes in patients with glioma through an univariable logistic regression. Whereas the multivariable logistic regression results showed only nCBF ASL (p = 0.008) was associated with tumor recurrence from post-treatment changes in patients with glioma with OR = 22.85, CI95%: (2.28-228.77).
Conclusion: In our study, ASL was the best technique, among the other two MRI PWI and the 18F-DOPA PET/CT PET, in distinguishing disease recurrence from post-treatment changes in treated glioma.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: